ECRI Institute Home About ECRI Institute Products and Services Conferences and Events Information For Patients
hdr3_col3Start Contact Us Report a Device Problem Careers SiteMap Frequently asked questions  
hdr3_row4Start hdr3_row4SearchECRI Go Search Tips  

Education and Events

Considerations for Implementing a Transcatheter Aortic Valve Implantation Service

An ECRI Institute Web Conference

Transcatheter aortic valve implantation (TAVI) is a percutaneous procedure intended to provide a new treatment option for patients with severe aortic stenosis who are not candidates for open valve replacement surgery and do not qualify for other treatment options.

Severe aortic stenosis is a life-threatening, progressive disease that affects approximately 360,000 individuals—predominantly age 65 or older—in the U.S. Currently, the FDA-approved indications for the procedure include inoperable severe aortic stenosis and patients who are operable but at high risk for complications or death.

In "Considerations for Implementing a Transcatheter Aortic Valve Implantation Service," presenters from ECRI Institute discuss the wide-ranging issues the procedure presents to hospitals, and preview findings from their technology assessment of TAVI.

This webinar: Who should listen?​
  • Provides safety and efficacy information to help inform patient selection
  • Helps health plan executives determine coverage policies
  • Addresses the complex infrastructure and staffing requirements for TAVI
  • Discusses the financial considerations and implications for creating a TAVI program
  • ​Hospital administrators
  • Value analysis and technology assessment committee members, including physicians and nurses
  • Health plan medical policy staff, including nurses and medical directors
  • Cardiac clinical service personnel



Questions?
 
1. On-demand web conference (download only)includes biographies and presentation slides:
$199
 (Free for qualifying ECRI Institute members)